Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 80Thoracic 26Gynecologic 21Genitourinary 18Head & Neck 16Breast 16Dermatologic 10Sarcoma 5CNS 4Other hematologic neoplasm 3Plasma cell 2Lymphoid 2Other solid neoplasm 1Other 1NET 1Myeloid 1Endocrine 1

Conditions

Multiple Myeloma 229Lymphoma 30Hematologic Neoplasms 21Recurrence 17Neoplasms 14Neoplasms, Plasma Cell 13Immunoglobulin Light-chain Amyloidosis 13Lymphoma, Non-Hodgkin 12Leukemia, Lymphocytic, Chronic, B-Cell 12Leukemia, Myeloid, Acute 10Lymphoma, Mantle-Cell 9Smoldering Multiple Myeloma 8Prostatic Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Myelodysplastic Syndromes 8Lymphoma, Large B-Cell, Diffuse 8Hodgkin Disease 8Ovarian Neoplasms 6Lung Neoplasms 6Leukemia, Plasma Cell 6Breast Neoplasms 6Waldenstrom Macroglobulinemia 5Melanoma 5Lymphoma, Follicular 5Monoclonal Gammopathy of Undetermined Significance 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Leukemia 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4

Interventions

Specimen Handling 2Magnetic Resonance Spectroscopy 2ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1sapanisertib 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1larotrectinib 1ipatasertib 1erdafitinib 1defactinib 1dabrafenib 1copanlisib 1capivasertib 1binimetinib 1adavosertib 1X-Rays 1Trastuzumab 1Sunitinib 1Paracentesis 1PF-05280014 1Ontruzant 1Ogivri 1Nuclear Medicine Department, Hospital 1Nivolumab 1Immunoglobulin G 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Esophageal Neoplasms × Plasma cell × 30 days × Clear all
NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT04314401 2026-05-13

National Cancer Institute "Cancer Moonshot Biobank"

National Cancer Institute (NCI)

Active not recruiting
1,600 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicOther hematologic neoplasmPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡